SCHEMBL3485396

SCHEMBL3485396

CC#CCc1c[nH]c(=O)[nH]c1=O

nearest known ligand 0.47

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ATAD2 Q6PL18 1/20 0.44
DPYD Q12882 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8508881 0.82 KMT2A (0.48)
SCHEMBL8509902 0.82 ATAD2 (0.33) ATAD2DPYD
SCHEMBL17060269 0.77 DPYD (0.52) ATAD2DPYD
SCHEMBL2043942 0.77 DPYD (0.52) ATAD2DPYD
SCHEMBL161148 0.76 ATAD2 (0.54) ATAD2DPYD
SCHEMBL2584919 0.74 LMNA (0.52) ATAD2DPYD
SCHEMBL4353311 0.73 DPYD (0.50) ATAD2DPYD
SCHEMBL5800398 0.73
SCHEMBL4794144 0.73 ATAD2 (0.47) ATAD2DPYD
SCHEMBL5962348 0.73 ATAD2 (0.47) ATAD2DPYD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2001522860-A 2001-11-20 JP claimed
EP-1027364-A2 PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS ISIS PHARMACEUTICALS, INC. (US) 2000-08-16 EP claimed
WO-1999024452-A9 PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS ISIS PHARMACEUTICALS INC (US) 1999-08-12 WO claimed
WO-1999024452-A2 PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS ISIS PHARMACEUTICALS, INC. (US) 1999-05-20 WO claimed
CN-106566855-B Nucleic acid amplification using reversibly modified oligonucleotides 苏州新海生物科技股份有限公司 2021-11-09 CN disclosed
CN-106566855-A Nucleic acid amplification using reversibly modified oligonucleotide 毕万里 2017-04-19 CN disclosed
CN-101495657-B Nucleic Acid Amplification Using Reversibly Modified Oligonucleotides 毕万里 2016-08-10 CN disclosed
US-9045522-B2 Nucleic acid amplification using a reversibly modified oligonucleotide Bi, Wanli (US) 2015-06-02 US disclosed
US-20130122507-A1 Nucleic Acid Amplification Using A Reversibly Modified Oligonucleotide SUZHOU NUHIGH BIOTECHNOLOGIES CO., LTD (CN) 2013-05-16 US disclosed
US-8334099-B2 Nucleic acid amplification using a reversibly modified oligonucleotide BI WANLI (US) 2012-12-18 US disclosed
EP-2049689-B1 NUCLEIC ACID AMPLIFICATION USING A REVERSIBLY MODIFIED OLIGONUCLEOTIDE BI WANLI (US) 2011-12-21 EP disclosed
US-20100021970-A1 Nucleic Acid Amplification Using a Reversibly Modified Oligonucleotide BI WANLI 2010-01-28 US disclosed
WO-1999024452-A9 PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS ISIS PHARMACEUTICALS INC (US) 1999-08-12 WO disclosed
EP-0923596-A2 LIPOPHILIC OLIGONUCLEOTIDE ANALOGS GILEAD SCIENCES, INC. (US) 1999-06-23 EP disclosed
WO-1999024452-A2 PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS ISIS PHARMACEUTICALS, INC. (US) 1999-05-20 WO disclosed
WO-1998004575-A2 LIPOPHILIC OLIGONUCLEOTIDE ANALOGS GILEAD SCIENCES, INC. (US) 1998-02-05 WO disclosed
WO-1997049723-A1 CATIONIC LIPIDS FOR DELIVERY OF NUCLEIC ACID TO CELLS GILEAD SCIENCES, INC. (US) 1997-12-31 WO disclosed
WO-1996001841-A1 CATIONIC LIPIDS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS GILEAD SCIENCES, INC. (US) 1996-01-25 WO disclosed
WO-1996001840-A1 CATIONIC LIPIDS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS GILEAD SCIENCES, INC. (US) 1996-01-25 WO disclosed
WO-1995029930-A2 IMPROVED METHOD FOR OLIGONUCLEOTIDE ANALOG SYNTHESIS GILEAD SCIENCES, INC. (US) 1995-11-09 WO disclosed